Search results for "NONALCOHOLIC FATTY LIVER DISEASE"

showing 9 items of 139 documents

Mechanisms inactivating the gene for E-cadherin in sporadic gastric carcinomas

2006

Nonalcoholic fatty liver disease (NAFLD) is the most common cause for elevated liver enzymes in the developed nations. Beyond prevention programs which are of particular interest because of the increasing number of overweight children, treatment should be focussed on the most important risk factors, obesity and insulin resistance. As a consequence of elucidating the pathomechanisms of NAFLD, the number of potential therapeutic options increased. However, many studies investigating the therapeutic effect show shortcomings in at least one of the following points: lack of a serial liver biopsy, short term of treatment and limited number of included patients. The second generation insulin sensi…

medicine.medical_specialtymedicine.diagnostic_testbusiness.industryInsulinmedicine.medical_treatmentFatty liverGastroenterologyGeneral MedicineLiver transplantationmedicine.diseaseBioinformaticsEndocrinologyInsulin resistanceLiver biopsyInternal medicineNonalcoholic fatty liver diseasemedicineRosiglitazonebusinessPioglitazonemedicine.drugWorld Journal of Gastroenterology
researchProduct

Fat and liver transplantation: clinical implications

2018

Nonalcoholic steatohepatitis (NASH), with or without hepatocellular carcinoma, is a growing indication for liver transplantation (LT) worldwide, particularly in the Western world. Patients with NASH typically combine features of metabolic syndrome with cardiovascular comorbidities, which challenge pre-LT evaluation, surgical approaches, post-LT management, and outcomes. Post-LT survival in NASH patients is excellent, similar to that achieved with other indications, particularly in the absence of cardiovascular comorbidities. Although disease recurrence on the liver allograft is common, progression to advanced disease is uncommon, at least in the short term. Whether this holds true with long…

medicine.medical_specialtymedicine.medical_treatmentDisease030230 surgeryLiver transplantation03 medical and health sciences0302 clinical medicineNon-alcoholic Fatty Liver DiseaseRecurrenceNonalcoholic fatty liver diseasemedicineHumansIntensive care medicineTransplantationbusiness.industrymedicine.diseaseTissue DonorsLiver TransplantationNatural historysurgical procedures operativeHepatocellular carcinomaDonation030211 gastroenterology & hepatologySteatosisMetabolic syndromebusinessTransplant International
researchProduct

Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease

2020

Introduction We investigated the longitudinal impact of antinuclear antibody (ANA) on clinical outcomes and survival in nonalcoholic fatty liver disease (NAFLD). Methods ANA were found in 16.9% of 923 biopsy-proven NAFLD patients, but none of them had histologic autoimmune hepatitis (AIH) or developed AIH after a mean follow-up of 106±50 months. Results Although ANA-positive cases had a higher prevalence of nonalcoholic steatohepatitis at baseline, the occurrence of liver-related events, hepatocellula carcinoma, cardiovascular events, extrahepatic malignancy, and overall survival were similar to ANA-negative. Discussion Once AIH has been ruled out, the long-term outcomes and survival are un…

musculoskeletal diseasesMalemedicine.medical_specialtyAntibodies Antinuclear; Biopsy; England; Female; Humans; Italy; Longitudinal Studies; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Prevalence; Prospective Studies; Survival AnalysisAnti-nuclear antibodyBiopsySettore MED/12 - GASTROENTEROLOGIAAntibodies Antinuclear Biopsy EnglandFemale Humans Italy Longitudinal Studies Male Middle Aged Non-alcoholic Fatty Liver Disease Prevalence Prospective StudiesSurvival AnalysisAutoimmune hepatitisMalignancyGastroenterologyAntibodies03 medical and health sciences0302 clinical medicineimmune system diseasesNon-alcoholic Fatty Liver DiseaseInternal medicineAntinuclearBiopsyNonalcoholic fatty liver diseasemedicineCarcinomaPrevalenceHumansLongitudinal StudiesProspective Studiesskin and connective tissue diseasesProspective cohort studySurvival analysisHepatologymedicine.diagnostic_testbusiness.industryGastroenterologyMiddle Agedmedicine.diseaseSurvival Analysisdigestive system diseases3. Good healthstomatognathic diseasesn/aEnglandItaly030220 oncology & carcinogenesisAntibodies Antinuclear030211 gastroenterology & hepatologyFemalebusiness
researchProduct

Betatrophin Levels Are Related to the Early Histological Findings in Nonalcoholic Fatty Liver Disease

2021

Betatrophin, a liver hormone, regulates glucose and lipid metabolism. We investigated the betatrophin levels in nonalcoholic fatty liver disease (NAFLD) and searched for any relationship with histological severity and metabolic parameters. Fifty males with NAFLD [Nonalcoholic Steatohepatitis (NASH) (n = 32)

nonalcoholic fatty liver disease0301 basic medicinemedicine.medical_specialtyBetatrophinEndocrinology Diabetes and Metabolismmedicine.medical_treatmentbetatrophin030209 endocrinology & metabolismMicrobiologydigestive systemBiochemistryArticle03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInsulin resistanceinsulin resistanceInternal medicineNonalcoholic fatty liver diseaseMedicineMolecular BiologyBetatrophin Glucose intolerance Insulin resistance Nonalcoholic fatty liver diseaseTriglyceridebusiness.industryInsulinnutritional and metabolic diseasesLipid metabolismmedicine.diseaseQR1-502digestive system diseases030104 developmental biologyEndocrinologyglucose intolerancechemistrySteatosisbusinessHormoneMetabolites
researchProduct

Etiological factors of chronic hepatitis in Italy: a 2014 national survey.

2017

Background The last Italian prevalence survey on chronic hepatitis (CH) conducted in 2001 showed that the hepatitis C virus (HCV) was the main agent associated with CH. Aim The aim of this study was to evaluate epidemiological changes in CH occurring after 13 years. Patients and methods Enrollment of 1392 CH consecutive patients referred to 16 Italian liver units in 2014 scattered all over the country (four in the North, four in the Center, four in the South, and four in the Islands) was performed. Results The mean age of the patients was 58.3 years, with a sex ratio (male/female) of 1.5. HCV infection (also with other etiologies) continues to be the most prevalent etiology (58.1%). However…

nonalcoholic fatty liver diseaseAdultMalemedicine.medical_specialtyPediatricsTime FactorsTime FactorAdolescentHepatitis C virusmedicine.disease_causemetabolic syndrome03 medical and health sciencesYoung Adult0302 clinical medicinechronic hepatitiRisk FactorsEpidemiologyNonalcoholic fatty liver diseasemedicinePrevalenceHumansAgedHepatitis ChronicHepatitisAged 80 and overHepatologybusiness.industryRisk FactorGastroenterologyEntecavirHepatitis CHealth SurveyHepatitis BHepatitis C ChronicMiddle Agedmedicine.diseaseHealth SurveysItaly030220 oncology & carcinogenesisEtiology030211 gastroenterology & hepatologyFemalehepatitis C virus infectionbusinessHumanmedicine.drugEuropean journal of gastroenterologyhepatology
researchProduct

MBOAT7 locus rs641738 variant predisposes to hepatocellular carcinoma in nonalcoholic fatty liver

2016

nonalcoholic fatty liver diseaseHepatologyHepatocellular carcinomabusiness.industrySettore MED/12 - GASTROENTEROLOGIAFatty liverGastroenterologyLocus (genetics)medicine.diseaseHepatocellular carcinoma; nonalcoholic fatty liver disease03 medical and health sciences0302 clinical medicineN/A030220 oncology & carcinogenesisHepatocellular carcinomaNonalcoholic fatty liver diseasemedicineCancer research030211 gastroenterology & hepatologybusinessDigestive and Liver Disease
researchProduct

Differences between current clinical guidelines for screening, diagnosis and management of non-alcoholic fatty liver disease and real-world practice:…

2021

International audience; INTRODUCTION: Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease and is associated with obesity and metabolic comorbidities. Liver steatosis can progress to nonalcoholic steatohepatitis (NASH) exhibiting a relevant risk of fibrosis and ultimately liver failure. To date, no approved treatment for NASH to reduce its clinical and humanistic burden has been developed. AREAS COVERED: We undertook a literature review to identify English language, national and international clinical guidelines for NAFLD regarding diagnosis, assessment and management, and determined their points of agreement and difference. Additionally, we investigated published liter…

nonalcoholic fatty liver diseaseNonalcoholic steatohepatitismedicine.medical_specialtyliterature review[SDV]Life Sciences [q-bio]Liver fibrosisdigestive systemGastroenterologyDiagnosis DifferentialLiver diseasereal-world practiceLiver steatosisNon-alcoholic Fatty Liver DiseaseInternal medicineNonalcoholic fatty liver diseasemedicineHumansMass Screeningnonalcoholic steatohepatitisliver fibrosisHepatologybusiness.industryGastroenterologynutritional and metabolic diseasesfood and beveragesmedicine.diseaseObesitydigestive system diseases[SDV] Life Sciences [q-bio]clinical guidelinesPractice Guidelines as Topicbusiness
researchProduct

The rs2294918 E434K variant modulates PNPLA3 expression and liver damage.

2015

The PNPLA3 rs738409 polymorphism (I148M) is a major determinant of hepatic fat and predisposes to the full spectrum of liver damage in nonalcoholic fatty liver disease (NAFLD). Aim of this study was to evaluate whether additional PNPLA3 coding variants contribute to NAFLD susceptibility, first in individuals with contrasting phenotypes (with early onset NAFLD vs. very low aminotransferases), and then in a large validation cohort. Rare PNPLA3 variants were not detected by sequencing coding regions and intron-exon boundaries either in 142 patients with early-onset NAFLD, nor in 100 healthy individuals with ALT A polymorphism (E434K sequence variant) was over-represented in NAFLD (adjusted p=0…

nonalcoholic fatty liver diseaselipid dropletgenetichepatic fat contentnonalcoholic steatohepatitis
researchProduct

Liver stiffness quantification in biopsy-proven nonalcoholic fatty liver disease patients using shear wave elastography in comparison with transient …

2021

Purpose: This study prospectively assessed the performance of liver stiffness measurements using point shear-wave elastography (p-SWE) in comparison with transient elastography (TE) in patients with biopsy-proven nonalcoholic fatty liver disease (NAFLD). Methods: Fifty-six consecutive adult patients with a histological diagnosis of NAFLD prospectively underwent TE and p-SWE on the same day. The median of 10 measurements (SWE-10), the first five (SWE-5), and the first three (SWE-3) measurements were analyzed for p-SWE. Liver biopsy was considered as the reference standard for liver fibrosis grade. Receiver operating characteristic (ROC) curves and areas under the ROC curves (AUROCs) were cal…

nonalcoholic fatty liver diseasemedicine.medical_specialtyGastroenterologySettore MED/01 - Statistica Medica030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineLiver stiffnessInternal medicineStatistical significanceBiopsyNonalcoholic fatty liver diseaseMedical technologymedicineRadiology Nuclear Medicine and imagingnonalcoholic steatohepatitisR855-855.5shear wave elastographymedicine.diagnostic_testReceiver operating characteristicbusiness.industryNonalcoholic fatty liver disease Nonalcoholic steatohepatitis Shear wave elastography Transient elastography Liver stiffnessmedicine.diseasetransient elastographyliver stiffnessLiver biopsyOriginal Article030211 gastroenterology & hepatologyElastographySettore MED/36 - Diagnostica Per Immagini E RadioterapiabusinessTransient elastographyUltrasonography
researchProduct